Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
AIM ImmunoTech to Present at the 'Virtual Investor 2023 Companies to Watch Event'
AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
AIM ImmunoTech Announces Corporate Governance Enhancements
AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting
AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease
Delaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Group's Nominations Valid
3
4
5
6
7
8
9
10
11
12
13
<<
<
>
>>
Privacy